17:05 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Verastem raises $150M in notes offering

Verastem Inc. (NASDAQ:VSTM) raised $150 million on Oct. 11 through the sale of 5% convertible senior notes due 2048. The notes have an initial conversion price of about $7.16, which is a 14% premium to...
17:38 , Sep 28, 2018 |  BC Week In Review  |  Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. The partners announced the deal on Sept....
15:43 , Sep 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample, cell culture and mouse studies suggest antagonizing AHR could help treat MM. In patients, high tumor levels of AHR correlated with poor survival. In multiple Velcade bortezomib-resistant and -sensitive...
22:43 , Sep 25, 2018 |  BC Extra  |  Company News

Verastem grants CSPC rights to Copiktra in China

Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan. On Monday, Copiktra became the first dual...
22:58 , Sep 14, 2018 |  BioCentury  |  Regulation

Closing NICE’s Orphan gap

As the list of Orphan drugs rejected by NICE grows, industry and patient groups are pressuring the agency to make broader use of tools that currently apply only to selected ultra-Orphan therapies. These tools allow...
23:41 , Sep 12, 2018 |  BC Extra  |  Politics & Policy

China biopharma stocks fall after centralized tendering talks

Stocks of Chinese biopharma companies slid on Wednesday, possibly in response to a meeting Tuesday of China's National Medical Insurance Bureau on the centralized procurement of generics. Under centralized procurement, a single generic manufacturer would...
17:59 , Aug 3, 2018 |  BC Week In Review  |  Company News

China Medical gains Chinese product rights in trio of deals

China Medical System Holdings Ltd. (HKSE:867) announced a series of deals in July under which it gained rights to several products in China, including Hong Kong, Macao and Taiwan. China Medical obtained exclusive rights from...
17:38 , Jul 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample and mouse studies suggest inhibiting NEK2 could help treat Velcade bortezomib-resistant MM. In MM patients, high levels of NEK2 in bone marrow plasma cells were associated with poor overall...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Shanghai Junshi licenses anti-PD-1 mAb to CSPC

Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize an undisclosed anti-PD-1 mAb in combination with...
19:56 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Celgene reports detailed PFS data for Pomalyst triple combo in Phase III for MM

Celgene Corp. (NASDAQ:CELG) reported additional data from the Phase III OPTIMISMM trial in 559 patients with relapsed or refractory multiple myeloma (MM) who received prior treatment with Revlimid lenalidomide showing that Pomalyst pomalidomide plus Velcade...